Cyclic Heavy Menstrual Bleeding and Lysteda
Links shared publicly online about this topic
LYSTEDA Available For Women With Cyclic Heavy Menstrual Bleeding
medicalnewstoday.com — “For an estimated 22 million women in America, monthly menstrual periods are so heavy they can sap energy, cause anemia, and interfere with daily activities. These sufferers of cyclic heavy menstr” View full resource at medicalnewstoday.com
Most Recently Shared on August 9, 2010 at 10:37 am By:
LYSTEDA Available For Women With Cyclic Heavy Menstrual Bleeding http://sns.ly/CJC48 #womenshealth
Lysteda available for heavy menstrual bleeding - MPR
empr.com — “Ferring Pharmaceuticals has launched Lysteda (tranexamic acid tablets) for the treatment of cyclic heavy menstrual bleeding (HMB) in women.” View full resource at empr.com
Most Recently Shared on June 21, 2010 at 2:37 pm By:
MPR News: Lysteda available for heavy menstrual bleeding: Ferring Pharmaceuticals has launched Lysteda (tranexamic... http://bit.ly/9tlIex
Lysteda approved for heavy menstrual bleeding - MPR
empr.com — “The FDA has approved Lysteda (tranexamic acid tablets, from Xanodyne), a non-hormonal treatment for women suffering from menorrhaghia, cyclic heavy menstrual bleeding (HMB).” View full resource at empr.com
Most Recently Shared on November 16, 2009 at 4:27 pm By:
MPR News: Lysteda approved for heavy menstrual bleeding: The FDA has approved Lysteda (tranexamic acid tablets, fro... http://bit.ly/3Mf1Lm
FDA Approves Lysteda to Treat Heavy Menstrual Bleeding
fda.gov — “The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.” View full resource at fda.gov
Most Recently Shared on November 13, 2009 at 8:53 pm By:
FDA Approves Lysteda to Treat Heavy Menstrual Bleeding http://ow.ly/BYBn
FDA Approves Lysteda To Treat Heavy Menstrual Bleeding
medicalnewstoday.com — “The U.S. Food and Drug Administration approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizi” View full resource at medicalnewstoday.com
Most Recently Shared on November 14, 2009 at 2:15 pm By:
FDA Approves Lysteda To Treat Heavy Menstrual Bleeding: The U.S. Food and Drug Administration approved Lysteda .. http://bit.ly/1jEN7M
Xanodyne Announces FDA Approval of Lysteda (Tranexamic Acid) for Treatment of Women with Heavy Menstrual Bleeding
drugs.com — “Lysteda (tranexamic acid) is used to treat menorrhagia. Includes Lysteda side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 17, 2009 at 12:19 am By:
FDA Approves Lysteda (Tranexamic Acid) for Treatment of Women with Heavy Menstrual Bleeding - http://bit.ly/2zep3v
Lysteda Approved for Heavy Menstrual Bleeding - Health News - Health.com
news.health.com — “Tranexamic acid (lysteda) has been approved by the u.s. food and drug administration as the first non-hormonal drug to treat heavy menstrual bleeding, a medical condition called menorrhagia. it works to stabilize a protein that helps blood clot.” View full resource at news.health.com
Most Recently Shared on November 16, 2009 at 4:01 pm By:
Lysteda Approved for Heavy Menstrual Bleeding: Tranexamic acid (Lysteda) has been approved by the U.S. Food and.. http://bit.ly/3F9ong
FDA OKs Menstrual Drug Lysteda
women.webmd.com — “The FDA has approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia).” View full resource at women.webmd.com
Most Recently Shared on November 13, 2009 at 11:06 pm By:
FDA OKs Menstrual Drug Lysteda: The FDA has approved Lysteda tablets (tranexamic acid), the first non-hormonal prod... http://bit.ly/47GHix
Xanodyne Announces FDA Approval Of Lysteda(TM) (Tranexamic Acid) For Treatment Of Women With Heavy Menstrual Bleeding
medicalnewstoday.com — “Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today ” View full resource at medicalnewstoday.com
Most Recently Shared on November 17, 2009 at 1:08 pm By:
Xanodyne Announces FDA Approval Of Lysteda(TM) (Tranexamic Acid) For Treatment Of Women With Heavy Menstrual Bl.. http://bit.ly/3VUjVK
Lysteda for the Management of Heavy Menstrual Bleeding | DrPullen.com – Medical and Health Blog
drpullen.com — “Lysteda for the Management of Heavy Menstrual Bleeding | DrPullen.com – Medical and Health Blog” View full resource at drpullen.com
Most Recently Shared on July 29, 2011 at 1:45 pm By:
Lysteda for the Management of Heavy Menstrual Bleeding | DrPullen.com – Medical and Health Blog http://fb.me/Ucuo3ECv
LYSTEDA - New Product Releases - MPR
empr.com — “Cyclic heavy menstrual bleeding.” View full resource at empr.com
Most Recently Shared on June 11, 2010 at 11:14 pm By:
MPR News: LYSTEDA: Tranexamic acid 650mg; tabs. http://bit.ly/9869u6
FDA approves Lysteda for treating menorrhagia
news-medical.net — “Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.” View full resource at news-medical.net
Most Recently Shared on November 16, 2009 at 5:24 pm By:
Stroke News: FDA approves Lysteda for treating menorrhagia: Xanodyne Pharmaceuticals, Inc., an inte.. http://twurl.nl/njohb3
Obstetrics And Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
medicalnewstoday.com — “Ferring Pharmaceuticals Inc. announced publication of one of its pivotal Phase 3 trials of LYSTEDA™ (tranexamic acid) tablets for cyclic heavy menstrual bleeding (HMB) in the October issue o” View full resource at medicalnewstoday.com
Most Recently Shared on October 8, 2010 at 12:37 pm By:
Obstetrics And Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study http://sns.ly/Ty355 #womenshealth
Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA
news-medical.net — “Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA" (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).” View full resource at news-medical.net
Most Recently Shared on May 10, 2010 at 3:00 pm By:
Stroke News: Ferring to acquire global rights to Xanodyne Pharmaceutical's LYSTEDA: Ferring Pharmaceuticals toda... http://twurl.nl/ozmlnd
Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB
news-medical.net — “Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.” View full resource at news-medical.net
Most Recently Shared on October 7, 2010 at 9:25 am By:
Stroke News: Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB: Ferring... http://twurl.nl/vvakzl
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Women's Health Line
The latest women's health news and research.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement

